What is Neuroblastoma?

Neuroblastoma is a solid tumour childhood cancer with the average age of diagnosis being just 2 years old.

It claims more lives of children under the age of 5 than any other cancer.

The average survival rate for aggressive neuroblastoma is only 50% and the rate for the most aggressive form of Neuroblastoma can be as tragically low as 15%. A third of the survivors of neuroblastoma have long term side effects from their actual treatments.

We need to improve treatments so they are more effective and less toxic and the way to do this is through research. Profits from Run2Cure go to neuroblastoma research projects. One research project that Run2Cure has contributed to for the last 3 years is called CBL137 and this is a drug being tested at Children’s Cancer Institute in Randwick. The drug has shown promising results and is planned to go into paediatric clinical trial in Australia and America shortly. Please visit www.neuroblastoma.org.au for more information.

By helping today you will help children diagnosed this year and in the future and lives will be saved.

Neuroblastoma does not need a miracle just more research!

Lowy Building
Lowy Research Centre
Research at CCIA

Uncovering the cause of NEUROBLASTOMA

glennProfessor Glenn Marshall’s research has reached an exciting stage as his team has identified the movement of a particular molecule as the first step in neuroblastoma tumour formation.
They are now working to determine if this movement occurs in the initiation of all childhood cancers, or whether it is specific to neuroblastoma.

The successful completion of this work will pave the way for prevention and/or strategies for early detection in children and therapies that destroy cancer cells effectively while leaving normal cells unharmed.

Lulu’s Story

Lulu was a bright, bubbly, joyous child with no health issues or concerns – but in 2010, when she was 8 months old, her family knew something was up.

“Lulu had a fever that wouldn’t go away,” explains Josi, Lulu’s mother. “At first we thought it was teething issues – but then we took her to hospital for further testing and never made it home after that.”

By the end of June, it was confirmed that Lulu had a grapefruit-sized tumour in her abdomen and extensive disease in her bones and bone marrow. She was diagnosed with stage 4 neuroblastoma.

Lulu’s lack of response to conventional treatment means that the family is now playing a terrifying waiting game and living day to day with no idea of the future or the next steps in Lulu’s journey. Lulu’s determination, courage and resilience to beat this dreadful disease is simply extraordinary.


The research undertaken at Children’s Cancer Institute is the key to uncovering safer, more effective treatments that are absolutely critical to families like Lulu’s.

Lulu and her mother Josi are part of Run2Cure again in 2017.

We can send a man to the moon and connect with each other online instantaneously, yet we haven’t progressed childhood cancer treatments for 20 years,” says Josi. “I know there’s a cure out there – we just need the funding, research and resources to find it.


Principal Partner


Platinum Sponsor


Gold Sponsors

Allcott Hire

Silver Sponsors

ESPA Current_RGB-01
Ausrise Logo

Bronze Sponsors

Ridel Logo for web